LGR5 expression is associated with prognosis in poorly differentiated gastric adenocarcinoma

Abstract

Background

Leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5) is an important cancer stem cell marker in gastric cancer. However, no detailed studies are available on LGR5 expression in poorly differentiated gastric adenocarcinoma (PD-AC). Therefore, we investigated the relationship between LGR5 expression and clinicopathological data in PD-AC.

Methods

LGR5 mRNA expression levels were quantified in 41 PD-AC specimens using a highly sensitive RNAscope in situ hybridization technique. Epstein–Barr virus (EBV) infection was also detected by EBV in situ hybridization.

Results

LGR5 expression levels were measured in 38 of 41 PD-AC cases, and 17 cases were identified as LGR5 high. The frequency of EBV positivity tended to be higher in the LGR5-low group than in the LGR5-high group (P = 0.0764). Furthermore, the frequency of vascular invasion tended to be higher in the LGR5-high group than in the LGR5-low group (P = 0.0764). The overall survival of PD-AC patients in the LGR5-high group was significantly lower than in the LGR5-low group (log-rank test, P = 0.0108). The Cox proportional hazard regression model revealed that the LGR5-low group (HR = 0.29; 95% CI: 0.11–0.74; P = 0.01) showed independently better OS for PD-AC.

Conclusions

Quantifying the levels of LGR5 expression may facilitate defining prognosis in Japanese patients with PD-AC. Further study of LGR5 in this context is warranted.

Background

Although the incidence of gastric cancer is decreasing, many individuals develop the disease. Gastric cancer is the fifth most frequent cancer and the third leading cause of cancer death [1]. Various treatment methods for gastric cancer, including surgery, radiation, and chemotherapy, have been performed. Among them, many recent studies have been conducted on cancer stem cells (CSCs), which are present in tumor tissues, and anti-CSC therapies have shown promising results [2]. CSCs are resistant to radiation and chemotherapy, and residual CSCs contribute to tumor regrowth. Therefore, effective anti-CSC therapy should be administered in combination with existing methods, such as chemotherapy and radiotherapy [3]. Some reports have investigated gastric CSCs, which typically express CD44, CD133, and Musashi-1 [4]. Additionally, leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5) was identified as a robust CSC marker in murine gastric cancer [5, 6].

The standard treatment for stage I gastric cancer is curative resection only, and it is associated with an excellent prognosis [7]. On the other hand, the standard treatment for stage II/III gastric cancer is curative resection and adjuvant chemotherapy, but the frequency of recurrence is high [8]. Therefore, it is necessary to improve the prognosis of stage II/III gastric cancer patients. Furthermore, the components of poorly differentiated cancer tissues also have a significant impact on prognosis. In gastric cancer, poorly differentiated adenocarcinoma (PD-AC) has a poor prognosis [9], but the underlying mechanisms remain unclear. Additionally, the expression of CSC markers in poorly differentiated gastric cancer, especially LGR5, has not been reported. Therefore, we investigated the clinicopathological relationship between LGR5 marker expression and prognosis in stage II/III gastric cancer patients.

Methods

Patients and materials

We identified 91 PD-AC cases who underwent surgical resection between 2008 and 2018 at six institutes [Shinshu University Hospital (Matsumoto, Japan), Nagano Municipal Hospital (Nagano, Japan), Aizawa Hospital (Matsumoto, Japan), Showa Inan General Hospital (Komagane, Japan), Iida Municipal Hospital (Iida, Japan), and Nagano Matsushiro General Hospital (Nagano, Japan)] and evaluated their clinicopathological features. Of these patients, stage II and III cases were selected. A re-evaluation by two pathologists (T.U. and H.O.) before analysis excluded five cases that did not contain poorly differentiated components, and 41 cases remained as candidates for analysis. This study was approved by the Ethics Committee of Shinshu University, Japan (no. 4088).

Histopathology, immunohistochemical staining, and evaluation

Paraffin blocks fixed with 8% formaldehyde containing sufficient tumor for analysis were prepared for hematoxylin and eosin (HE) staining and tissue microarray (TMA) analysis by extracting a core with a diameter of 3 mm from each case. Additionally, the TMA was subjected to immunostaining using antibodies against the following mismatch repair proteins (MMRPs): MLH1 (ES05; mouse monoclonal; dilution 1:50), PMS2 (EP51; rabbit monoclonal; dilution 1:40), MSH2 (FE11; mouse monoclonal; dilution 1:50), or MSH6 (EP49; rabbit monoclonal; dilution 1:50; Agilent Technologies, Santa Clara, CA, USA), as described previously [10]. Representative images of the slides were captured with an Olympus DP74 camera (lens, × 40; Olympus, Tokyo, Japan) using the CellSens Standard software (Olympus, Tokyo, Japan). The images were acquired at a resolution of 96 dpi and Adobe Photoshop was used to enhance the resolution of the images to 300 dpi. As reported in our previous paper, the staining results were scored as positive when a nuclear staining pattern was observed. If at least one of the four antibodies did not show expression, MMR protein deficiency was indicated. In the tumor, the tumor-infiltrating lymphocyte (TIL) score was assessed using a four-tier scale and recorded as follows: none: 0; mild: 1; moderate: 2; and marked: 3 [11]. The TIL score was classified as low grade (scores 0 and 1) and high grade (2 and 3).

EBER in situ hybridization

The EBER in situ hybridization assay was performed on TMA block sections. Epstein–Barr virus (EBV) was identified using EBER probes (ISH iVIEW Blue detection kit; Ventana Medical Systems Inc., Oro Valley, AZ, USA).

LGR5 RNA in situ hybridization

LGR5 mRNA detection was performed using the RNAscope® kit (Advanced Cell Diagnostics, Hayward, CA, USA), as described previously [10]. Additionally, a four-step evaluation method we reported previously was used [10]. Furthermore, LGR5 mRNA expression levels were categorized as low expression (grades 0, 1+, 2+, and 3+) and high expression (4+). We analyzed the relationship between LGR5 expression levels and the clinicopathological data and prognosis in patients with PD-AC, particularly regarding overall survival (OS).

TCGA analysis

mRNA-seq analysis was performed using the TCGA database. The TCGA data were downloaded from cBioPortal (http://www.cbiopor- tal.org/) in the form of mRNA median values. All clinical and pathological data for the TCGA cohort were downloaded from cBioPortal. The TCGA cohort was classified into high or low LGR5 mRNA expression groups. LGR5 high indicates LGR5 mRNA expression ≥ the median, and LGR5 low indicates LGR5 mRNA expression < the median. Stage II/III patients were included in the first analysis, and then only Stage II/III patients with histological grade 3 were included in the second analysis.

Statistical analysis

The chi-squared test was applied to assess statistical significance. A P-value < 0.05 was considered to be statistically significant. The OS rates of PD-AC patients were calculated using the Kaplan–Meier method, and differences were compared using the log-rank test. Univariate and multivariate analyses for prognostic factors were performed using the Cox proportional hazard regression model. A P-value < 0.05 was considered to be statistically significant. Statistical analysis was performed using JMP version 13 (SAS Institute Japan, Tokyo, Japan).

Results

LGR5 expression in PD-AC

In PD-AC patients, 38 of 41 cases showed LGR5 expression. Among them, 17 cases were identified as LGR5 high (Fig. 1a and b). Moreover, LGR5 expression was completely absent in three cases (Fig. 1d and e). LGR5 expression varied from diffuse to scattered.

Fig. 1.

Representative images of LGR5 and EBV. Representative features in LGR5-high expression (a and b) and LGR5-low expression (d and e) cases. LGR5-high expression cases show EBV negativity (c). LGR5-low expression cases show EBV positivity (f). a and d, HE; b and e, LGR5; c and f, EBV

Relationship between LGR5 expression and clinicopathological characteristics

EBER expression was negative in most cases (Fig. 1c). Although there were few EBV-positive PD-AC cases (Fig. 1f), all exhibited low LGR5 expression. LGR5 expression and clinicopathologic data are shown in Table 1. The number of EBV-positive PD-AC cases tended to be higher in the LGR5-low expression group than in the LGR5-high expression group (P = 0.0764). The frequency of vascular invasion tended to be higher in the LGR5-high expression group than in the LGR5-low expression group (P = 0.0764). No significant difference was found between the LGR5-high expression group and LGR5-low expression group regarding TILs, MSI, histological subtype, or TNM stage.

Table 1.

LGR5 expression and clinicopathological characteristics in PD-AC

Factors	LGR5 expression
	n	High (n = 17)	Low (n = 24)	P-value
Age				0.0472
> 74 years	19	11	8
≤ 74 years	22	6	16
Sex				0.0498
Male	24	13	11
Female	17	4	13
EBV				0.0764
Positive	4	0	4
Negative	37	17	20
Vascular invasion				0.0764
Present	37	17	20
Absent	4	0	4
TIL				0.283
High	25	9	16
Low	16	8	8
MSI				0.2176
Present	19	10	9
Absent	21	7	14
Differentiated-type				0.2921
Solid-type 1	8	2	6
Non-solid-type 2	33	15	18
TNM stage				0.9382
II	19	8	11
III	22	9	13

Prognostic value of LGR5 in PD-AC

The prognostic value of LGR5 expression in PD-AC was analyzed by the Kaplan–Meier method and log-rank test (Fig. 2). The median OS for the study patients was 1146 (range; 635.5–1718) days. A significant difference was found in OS between PD-AC cases in the LGR5-high expression group [median OS: 756 (range; 154.5–1306.5) days] and LGR5-low expression group [median OS: 1338 (range; 922.75–2022.75) days] (log-rank test, P = 0.0108).

Fig. 2.

Prognostic value of LGR5 in PD-AC by Kaplan–Meier analysis. A significant difference was found in OS between PD-AC cases in the LGR5-high expression group [median OS; 756 (range; 154.5–1306.5) days] and LGR5-low expression [median OS; 1338 (range; 922.75–2022.75) days; log-rank test, P = 0.0108]

We also compared the first quartile with grades 0–2 and the fourth quartile with grade 4. A significant difference was found in OS between PD-AC cases in the first and fourth quartiles (log-rank test, P = 0.0072).

We evaluated the relationship between clinicopathological factors and LGR5 expression regarding OS using a Cox proportional hazard regression model (Table 2), which revealed that the LGR5-low expression group (HR = 0.29; 95% CI: 0.11–0.74; P = 0.01) had independently better OS for PD-AC.

Table 2.

Univariate and multivariate analyses of prognostic factors for PD-AC

Factors	Univariate analysis		Multivariate analysis
	HR (95% CI)	P-value	HR (95% CI)	P-value
Age: > 74 years vs ≤ 74 years	1.49 (0.57–3.69)	0.3986
Sex: Male vs Female	0.65 (0.26–1.69)	0.3596
Vascular invasion: Present vs Absent	3.07 (0.64–55.22)	0.1936
TIL: Low vs High	1.94 (0.77–4.86)	0.1575
MSI: Present vs Absent	2.07 (0.79–5.39)	0.1338
TNM stage: II vs III	0.39 (0.15–0.97)	0.0425	0.36 (0.13–0.89)	0.026
LGR5: High vs Low	3.18 (1.24–8.39)	0.0161	3.48 (1.36–9.22)	0.01

TCGA data analysis

First, we examined the LGR5 mRNA expression levels in the TCGA cohort of stage II/III patients. There was no significant difference in OS between the LGR5 high and low groups (log-rank test, P = 0.7175). Univariate and multivariate analyses for prognostic factors were performed using the Cox proportional hazard regression model. However, there was no significant difference in the univariate analysis of the TCGA cohort (HR = 0.93; 95% CI: 0.64–1.35; P = 0.72).

We then examined the LGR5 mRNA expression levels in the TCGA cohort when stage II/III patients were limited to those with histological grade 3. There was no significant difference in OS between the LGR5 high and low groups (log-rank test, P = 0.7198). Univariate and multivariate analyses for prognostic factors were performed using the Cox proportional hazard regression model. However, there was no significant difference in the univariate analysis of the TCGA cohort (HR = 1.08; 95% CI: 0.70–1.67; P = 0.72).

Discussion

LGR5 is an independent prognostic factor in PD-AC stages II and III. Although PD-AC has a poor prognosis [9], the related factors are not well understood. PD-AC exists as solid and non-solid subtypes. The prognosis of patients with the non-solid subtype with fibrosis is poor [12]. In our study, most PD-AC cases were non-solid, but no clear difference was observed in the prognosis of both non-solid and solid subtypes. LGR5 is also a promising gastric CSC marker, and high LGR5 expression in the poor prognosis group may suggest an involvement of CSCs in determining the prognosis. Therefore, LGR5 may be a therapeutic target in PD-AC and improve PD-AC patient prognoses.

Migration ability and epithelial-mesenchymal transition (EMT) are increased in poorly differentiated gastric cancer [13]. Therefore, the poor prognosis of patients with high LGR5 expression may be related to the histological features of poorly differentiated cancer represented by enhanced migration ability, EMT-related protein expression, and LGR5 expression. Cancer cell migration is known to affect prognosis in gastric cancer [13]. Additionally, LGR5 expression, although not in the stomach, is related to migration ability and EMT [14]. In our study, the correlation between vascular invasion and high LGR5 expression may support an association of LGR5 expression with EMT. High LGR5 expression and EMT were reported to be correlated in gastric cancer [15, 16]. Furthermore, Zhang et al. reported that the LGR5 ligand RSPO2 promotes EMT in gastric cancer cells by activating WNT/β-catenin signaling via LGR5 [17]. Therefore, elucidation of the relationship between LGR5 and RSPO2 in PD-AC may lead to the development of new therapeutic methods and an improved prognosis for PD-AC.

LGR5 expression in the tumors of various organs has been widely investigated, mainly using immunostaining. Although some reports have indicated that high LGR5 expression is associated with a poor prognosis [18, 19], others have used RNAscope, which is considered to be more reliable [20, 21], and have reported that high LGR5 expression correlates with a good prognosis specifically in pancreatic ductal adenocarcinoma [21]. We previously utilized RNAscope and showed that high LGR5 expression might be a poor prognostic factor in breast cancer [22].

Several reports have investigated LGR5 expression in gastric cancer. One RNAscope-based study did not uncover any difference in the OS of gastric cancer patients with varying expression of LGR5 [23]. In other study of gastric cancer, high immunostaining scores for LGR5 were significantly associated with an increased risk of death [24]. Taken together, these data indicate that the role of LGR5 may be tissue-specific, and that its protein and mRNA regulation may be more complex than it seems.

While in our study, higher levels of LGR5 expression were associated with adverse prognosis, no significant differences in the overall survival were detected in TCGA cohort. This discrepancy might be due to ethnic or technical differences.

In addition, Bu et al. reported that LGR5 expression is associated with a favorable prognosis, although this was limited to stages I and II [25]. Furthermore, LGR5 expression was associated with a high stage and lymph node metastasis [23]. Xi et al. reported that high LGR5 expression is associated with poorly differentiated cancer [26]. However, Bu et al. reported that LGR5 is highly expressed in well-differentiated cancer [25]. Additionally, in studies using RNAscope, high LGR5 expression is correlated with well-differentiated cancer [27]. However, there is no comparison between LGR5 expression and prognosis in PD-AC using RNAscope, and the association between high LGR5 expression and poor prognosis in poorly differentiated cancer is a new finding.

The tendency for low LGR5 expression in EBV-positive tumors may be a feature of EBV-associated gastric cancer. According to a novel molecular pathological classification [28], EBV-associated gastric cancer is recognized as a distinct type of gastric cancer with a good prognosis [29]. The Cancer Genome Atlas Research Network reports that gastric cancer is divided into four types [28]. Therefore, to accumulate further knowledge in the future, it is necessary to analyze LGR5 expression in each type.

Our study has some limitations. This study included a relatively small sample size, which may have led to unreliable estimates. LGR5 expression and migration must be investigated in cultured cells; additionally, LGR5 expression must be analyzed in EBV-infected cells.

Conclusions

The association of LGR5 expression and patient prognosis in poorly differentiated gastric cancer may be applicable to the development of LGR5 targeted therapy and prognostic markers, but further study is desired.

Abbreviations

CSC

Cancer stem cell

LGR5

Leucine-rich repeat-containing G-protein-coupled receptor 5

PD-AC

Poorly differentiated adenocarcinoma

TMA

Tissue microarray

TILs

Tumor-infiltrating lymphocytes

OS

Overall survival

EMT

Epithelial-mesenchymal transition

Authors’ contributions

TE participated in the design of the study, performed the pathological analysis, and drafted the manuscript. TU, SK, SA, and MI helped with the pathological analysis. TU performed the statistical analysis. TN and YK conducted immunohistochemistry. TE and US examined the clinical data of cases. HO and TU critically revised the draft for important intellectual content. All authors have read and approved the manuscript.

Funding

This study was partially supported by the Hokuto Foundation for Bioscience (grant awarded to T.U.). The funding body had no role in the study design, collection, analysis, or interpretation of data or manuscript writing. The authors declare no conflicts of interest.

Availability of data and materials

All data generated and analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

This study was approved by the Ethics Committee of Shinshu University School of Medicine (Approval Code: 4088). The requirement of informed consent was waived, and an opt-out method was used because of the retrospective design of the study. The investigation was conducted in compliance with the Helsinki Declaration.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.